How should progesterone be prescribed for a 46-year-old woman with irregular menstrual periods?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Progesterone Treatment for Irregular Periods in a 46-Year-Old Woman

For a 46-year-old woman with irregular periods, prescribe oral micronized progesterone 200 mg daily at bedtime for 10-14 days per month to regulate menstrual cycles and protect the endometrium. 1

Dosing Regimen

The standard approach for perimenopausal irregular bleeding is cyclic progesterone therapy:

  • Micronized progesterone 200 mg orally at bedtime for 12-14 days every 28 days 1
  • Alternative: 400 mg daily for 10 days if treating secondary amenorrhea 2
  • Take at bedtime to minimize drowsiness and dizziness 2

Why micronized progesterone is preferred: Among progestational agents, micronized progesterone is the first-line choice because it carries lower cardiovascular and thrombotic risks compared to synthetic progestins like medroxyprogesterone acetate (MPA) 3, 4. The 2017 AACE position statement specifically notes that micronized progesterone may have better outcomes regarding cardiovascular effects, blood pressure, venous thromboembolism, stroke, and breast cancer compared to MPA 4.

Alternative Progestin Options

If micronized progesterone is not tolerated or unavailable:

  • Medroxyprogesterone acetate (MPA) 5-10 mg for 10-12 days/month 1
  • Norethindrone acetate 5 mg for 10-12 days/month 1

Important caveat: Continuous daily progestogen (rather than cyclic) is NOT recommended at this age due to concerns about increased breast cancer risk with continuous progesterone exposure 5.

Clinical Considerations for This Age Group

At 46 years old, this patient is likely perimenopausal. Key points:

  • Cyclic progestogen protects against endometrial hyperplasia that can develop from unopposed estrogen during anovulatory cycles 1
  • Expect withdrawal bleeding 2-7 days after completing each progestogen course 2
  • Long-cycle therapy (progesterone for 14 days every 3 months) may be considered to reduce breast exposure to progestogens, though efficacy data is limited 5

Monitoring and Follow-up

  • If irregular bleeding persists or worsens, perform endometrial sampling to rule out hyperplasia or malignancy 1
  • Any unexpected bleeding pattern (not withdrawal bleeding) requires evaluation 1
  • Consider adjusting dose based on BMI: higher BMI patients may require higher doses to achieve adequate serum progesterone levels 6

Contraindications to Check

Before prescribing, ensure the patient does NOT have:

  • Peanut allergy (micronized progesterone capsules contain peanut oil) 2
  • Unexplained vaginal bleeding (requires evaluation first) 2
  • Current or history of breast cancer 2
  • Active liver disease 2
  • Known or suspected pregnancy 2

If Estrogen is Also Needed

If the patient has significant vasomotor symptoms (hot flashes), consider adding estrogen. In that case:

  • Transdermal estradiol is preferred over oral to avoid hepatic first-pass effects and reduce thrombotic risk 1, 5
  • Continue progesterone 200 mg for 12 days per 28-day cycle for endometrial protection 1, 2

References

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Guideline

american association of clinical endocrinologists and american college of endocrinology position statement on menopause-2017 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2017

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause: executive summary of recommendations.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.